Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

docetaxel
BRAF
cancer chemotherapy
lung carcinoma
platinum-based chemotherapy
  • 0 views
  • 14 Jul, 2022
  • 40 locations
Encorafenib Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma. Dose escalation phase: Previously treated or treatment-nave patients will be evaluated after the

  • 0 views
  • 30 Jan, 2021
  • 1 location
Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer

the different kinome profiles and the safety profile to the combination of palbociclib and binimetinib.

BRCA1
mammogram
BRCA2
triple negative breast cancer
palbociclib
  • 0 views
  • 16 Sep, 2021
  • 8 locations
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)

This is a single-centre, open-label Phase II study of the investigational drugs binimetinib and encorafenib that will be taken my mouth (orally) daily in adult patient with advanced and/or

neutrophil count
cancer
growth factor
BRAF
metastasis
  • 0 views
  • 09 Feb, 2022
  • 1 location
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL)

Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1 will include patients with asymptomatic brain metastases and cohort 2 will include patients with symptomatic brain metastasis.

neutrophil count
targeted therapy
BRAF
platelet count
stereotactic radiosurgery
  • 10 views
  • 24 Mar, 2022
  • 20 locations
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

This phase II trial studies the effects of binimetinib and encorafenib in treating patients with melanoma that has spread to the central nervous system (metastases). Binimetinib and encorafenib

  • 0 views
  • 08 Mar, 2022
  • 1 location
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for

lung carcinoma
Accepts healthy volunteers
KRAS
systemic therapy
  • 0 views
  • 06 Apr, 2022
  • 1 location
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and

  • 0 views
  • 28 Dec, 2021
  • 1 location
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.

  • 3 views
  • 18 Jun, 2022
  • 1 location
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

This is a Phase I/Ib study whose purpose is to find out if combining an experimental drug called binimetinib with pembrolizumab is beneficial in people who have advanced non-small cell lung

  • 7 views
  • 30 May, 2022
  • 1 location